The global market for Cancer / Tumor Profiling was valued at US$12.1 Billion in 2024 and is projected to reach US$21.3 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Tumor profiling offers comprehensive insights into the genetic landscape of cancers, facilitating the development of targeted therapies aimed at specific genetic alterations. This approach notably transformed the treatment of lung cancer, with therapies targeting EGFR mutations being among the earliest successful examples. Beyond pinpointing individual mutations, profiling elucidates the broader molecular framework of cancer progression and resistance mechanisms, paving the way for combination therapies to combat resistance. Additionally, the identification of biomarkers through profiling can predict patient responses to immunotherapy, enabling more personalized treatment regimens. The integration of liquid biopsy techniques, such as ctDNA and CTC analysis, further augments profiling capabilities, allowing non-invasive, real-time monitoring of tumor dynamics and minimal residual disease.
The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.
Global Cancer / Tumor Profiling Market - Key Trends & Drivers Summarized
The advent of molecular profiling, driven by genomics and next-generation sequencing (NGS), is revolutionizing personalized cancer treatment. By using tissue samples and less invasive liquid biopsies, molecular profiling identifies genetic mutations and fusions that are crucial for personalized cancer therapies. In recent years, the application of DNA/RNA sequencing on formalin-fixed, paraffin-embedded (FFPE) tissues significantly enhanced the ability to pinpoint actionable targets within tumors. Nevertheless, having a druggable target does not necessarily ensure its role in disease progression or clinical efficacy. Effective molecular profiling necessitates advanced technical skills and a profound understanding of tumor biology and associated therapies, especially in cases lacking standardized treatments where NGS provides alternative therapeutic options.Tumor profiling offers comprehensive insights into the genetic landscape of cancers, facilitating the development of targeted therapies aimed at specific genetic alterations. This approach notably transformed the treatment of lung cancer, with therapies targeting EGFR mutations being among the earliest successful examples. Beyond pinpointing individual mutations, profiling elucidates the broader molecular framework of cancer progression and resistance mechanisms, paving the way for combination therapies to combat resistance. Additionally, the identification of biomarkers through profiling can predict patient responses to immunotherapy, enabling more personalized treatment regimens. The integration of liquid biopsy techniques, such as ctDNA and CTC analysis, further augments profiling capabilities, allowing non-invasive, real-time monitoring of tumor dynamics and minimal residual disease.
The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.
Scope of the Study
The report analyzes the Cancer / Tumor Profiling market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments:
Technology (Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry, Other Technologies); Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer Types); Application (Research Application, Clinical Application).Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Immunoassays Technology segment, which is expected to reach US$6.7 Billion by 2030 with a CAGR of a 9.4%. The Next Generation Sequencing Technology segment is also set to grow at 10.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $4.1 Billion in 2024, and China, forecasted to grow at an impressive 10.6% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Agilent Technologies, Inc., Caris Life Sciences, Exact Sciences Corporation, Guardant Health, Inc., Hologic, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cancer / Tumor Profiling Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer / Tumor Profiling Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cancer / Tumor Profiling Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 55 major companies featured in this Cancer / Tumor Profiling market report include:
- Agilent Technologies, Inc.
- Caris Life Sciences
- Exact Sciences Corporation
- Guardant Health, Inc.
- Hologic, Inc.
- Illumina SAPAC
- IMB Dx, Inc.
- Lucence Health, Inc.
- NeoGenomics Laboratories Inc.
- Roche Sequencing Solutions, Inc.
- Sysmex Corporation
- Tempus Labs
- Thermo Fisher Scientific Inc.
Table of Contents
I. METHODOLOGYMII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies, Inc.
- Caris Life Sciences
- Exact Sciences Corporation
- Guardant Health, Inc.
- Hologic, Inc.
- Illumina SAPAC
- IMB Dx, Inc.
- Lucence Health, Inc.
- NeoGenomics Laboratories Inc.
- Roche Sequencing Solutions, Inc.
- Sysmex Corporation
- Tempus Labs
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 376 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 12.1 Billion |
| Forecasted Market Value ( USD | $ 21.3 Billion |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
